A review of co-milling techniques for the production of high dose dry powder inhaler formulation

References

• Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56:588–99.
   PubMed Web of Science ®Google Scholar
• Patton JS. Mechanisms of macromolecule absorption by the lungs. Adv Drug Deliv Rev. 1996;19:3–36.
   Web of Science ®Google Scholar
• Adjei A. Inhalation delivery of therapeutic peptides and proteins. U.K.: CRC Press Taylor and Francis group; 1997.
   Google Scholar
• Somers GI, Lindsay N, Lowdon BM, et al. A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. Drug Metab Dispos. 2007;35:1797–805.
   PubMed Web of Science ®Google Scholar
• Hoppentocht M, Hagedoorn P, Frijlink HW, de Boer AH. Technological and practical challenges of dry powder inhalers and formulations. Adv Drug Deliv Rev. 2014;75:18–31.
   PubMed Web of Science ®Google Scholar
• Somayaji R, Parkins MD. Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomas aeruginosa infection in cystic fibrosis. Ther Deliv. 2015;6:121–37.
   PubMedGoogle Scholar
• Cavaiola ST, Edelman S. Inhaled insulin: a breath of fresh air? A review of inhaled insulin. Clin Ther. 2014;36:1275–89.
   PubMed Web of Science ®Google Scholar
• Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov. 2014;13:655–72.
   PubMed Web of Science ®Google Scholar
• Geller DE, Weers J, Heuerding S. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology. J Aerosol Med Pulm Drug Deliv. 2011;24:175–82.
   PubMed Web of Science ®Google Scholar
• Weers J, Tarara T. The PulmoSphere™ platform for pulmonary drug delivery. Ther Deliv. 2014;5:277–95.
   PubMedGoogle Scholar
• Goldberg T, Wong E. Afrezza (Insulin Human) inhalation powder: A new inhaled insulin for the management of type-1 or type-2 diabetes mellitus. P T. 2015;40:735–41.
   PubMedGoogle Scholar
• Berkenfeld K, Lamprecht A, McConville JT. Devices for dry powder drug delivery to the lung. AAPS PharmSciTech. 2015;16:479–90.
   PubMed Web of Science ®Google Scholar
• Claus S, Weiler C, Schiewe J, Friess W. How can we bring high drug doses to the lung? Eur J Pharm Biopharm. 2014;86:1–6.
   PubMed Web of Science ®Google Scholar
• Chan JG, Wong J, Zhou QT, et al. Advances in device and formulation technologies for pulmonary drug delivery. AAPS PharmSciTech. 2014;15:882–97.
   PubMed Web of Science ®Google Scholar
• Morton DAV, Staniforth J, inventors; Vectura Ltd, assignee. Dry powder composition comprising co-jet milled particles for pulmonary inhalation. WIPO patent, WO 2005025536 A9, 2005.
   Google Scholar
• Coelho MC, Harnby N. Moisture bonding in powders. Powder Technol. 1978;20:201–5.
   Web of Science ®Google Scholar
• Padmadisastra Y, Kennedy RA, Stewart PJ. Influence of carrier moisture adsorption capacity on the degree of adhesion of interactive mixtures. Int J Pharm. 1994;104:R1–4.
   Web of Science ®Google Scholar
• Young PM, Price R. The influence of humidity on the aerosolisation of micronised and SEDS produced salbutamol sulphate. Eur J Pharm Sci. 2004;22:235–40.
   PubMed Web of Science ®Google Scholar
• Young PM, Price R, Tobyn MJ, et al. Effect of humidity on aerosolization of micronized drugs. Drug Dev Ind Pharm. 2003;29:959–66.
   PubMed Web of Science ®Google Scholar
• Musa R, Ventura P, Chiesi P, inventors; Chiesi Farmaceutici S.P.A., assignee. Improved powdery pharmaceutical compositions for inhalation. WIPO patent, WO 2000053157 A1, 2000.
   Google Scholar
• Lakio S, Morton DAV, Ralph AP, Lambert P. Optimizing aerosolization of a high-dose L-arginine powder for pulmonary delivery. Asian J Pharmacol. 2015;10:528–40.
   Google Scholar
• Brodka-Pfeiffer K, Langguth P, Grass P, Hausler H. Influence of mechanical activation on the physical stability of salbutamol sulphate. Eur J Pharm Biopharm. 2003;56:393–400.
   PubMed Web of Science ®Google Scholar
• Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm. 2010;392:1–19.
   PubMed Web of Science ®Google Scholar
• Malcolmson RJ, Embleton JK. Dry powder formulations for pulmonary delivery. Pharm Sci Technol Today. 1998;1:394–8.
   Google Scholar
• Feeley JC, York P, Sumby BS, Dicks H. Determination of surface properties and flow characteristics of salbutamol sulphate, before and after micronisation. Int J Pharm. 1998;172:89–96.
   Web of Science ®Google Scholar
• Chow AH, Tong HH, Chattopadhyay P, Shekunov BY. Particle engineering for pulmonary drug delivery. Pharm Res. 2007;24:411–37.
   PubMed Web of Science ®Google Scholar
• Starkey D, Taylor C, Morgan N, et al. Modeling of continuous self-classifying spiral jet mills part 1: model structure and validation using mill experiments. AIChE J. 2014;60:4086–95.
   Web of Science ®Google Scholar
• Starkey D, Taylor C, Siddabathuni S, et al. Modeling of continuous self-classifying spiral jet mills part 2: powder-dependent parameters from characterization experiments. AIChE J. 2014;60:4096–103.
   Web of Science ®Google Scholar
• Salman AD, Ghadiri M, Hounslow MJ, editors. Handbook of powder technology. Vol. 12. Particle breakage. 1st ed. Amsterdam: Elsevier; 2007.
   Google Scholar
• Saleem IY, Smyth HDC. Micronization of a soft material: Air-jet and micro-ball milling. AAPS PharmSciTech. 2010;11:1642–9.
   PubMed Web of Science ®Google Scholar
• Midoux N, Hosek P, Pailleres L, Authelin JR. Micronization of pharmaceutical substances in a spiral jet mill. Powder Technol. 1999;104:113–20.
   Web of Science ®Google Scholar
• Skelton R, Khayyat A, Temple R. Fluid energy milling-an investigation of micronizer performance. Fine Particles Process. 1980;1:113–25.
   Google Scholar
• Zugner S, Marquardt K, Zimmermann I. Influence of nanomechanical crystal properties on the comminution process of particulate solids in spiral jet mills. Eur J Pharm Biopharm. 2006;62:194–201.
   PubMed Web of Science ®Google Scholar
• Vatsaraj NB, Gao D, Kowalski DL. Optimization of the operating conditions of a lab scale Aljet mill using lactose and sucrose: a technical note. AAPS PharmSciTech. 2003;4:141–6.
   Google Scholar
• Morton DAV, Staniforth J, Tobyn M, Eason S, Harmer Q, Ganderton D, inventors; Vectura Limited, assignee. Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation. WIPO patent, WO 200502550 A1, 2005.
   Google Scholar
• Staniforth JN, Morton DAV, Tobyn M, Eason S, Harmer Q, Ganderton D, inventors; Vectura Limited, assignee. Pharmaceutical compositions comprising apomorphine for pulmonary inhalation. WIPO patent, WO 2004089374 A1, 2004.
   Google Scholar
• Stank K, Steckel H. Physico-chemical characterisation of surface modified particles for inhalation. Int J Pharm. 2013;448:9–18.
   PubMed Web of Science ®Google Scholar
• Steckel H, Stank K. Powder processing: Performance improvements through co-milling. Respir Drug Deliv. 2014;1:89–98.
   Google Scholar
• Loh ZH, Samanta AK, Heng PWS. Overview of milling techniques for improving the solubility of poorly water-soluble drugs. Asian J Pharmacol. 2015;10:255–74.
   Web of Science ®Google Scholar
• Staniforth JN, Green MMJ, Morton DAV, inventors; Vectura Limited, assignee., Method of making particles for use in a pharmaceutical composition. US Patent, US 7736670 B2, 2010.
   Google Scholar
• Aulton ME, Taylor KMG, editors. Aulton's pharmaceutics. 4th ed. London: Churchill Livingstone; 2013.
   Google Scholar
• Gamblin RL, inventor; Gamblin R.L., assignee. Planetary grinding apparatus. US patent, US 5205499 A, 1993.
   Google Scholar
• Chen Y, Lian X, Li Z, et al. Effects of rotation speed and media density on particle size distribution and structure of ground calcium carbonate in a planetary ball mill. Adv Powder Technol. 2015;26:505–10.
   Web of Science ®Google Scholar
• Rosenkranz S, Breitung-Faes S, Kwade A. Experimental investigations and modelling of the ball motion in planetary ball mills. Powder Technol. 2011;212:224–30.
   Web of Science ®Google Scholar
• Fukumori Y, Tamura I, Jono K, et al. Dry grinding of chitosan powder by a planetary ball mill. Adv Powder Technol. 1998;9:281–92.
   Web of Science ®Google Scholar
• Zhao Q-Q, Jimbo G. The effect of grinding media on the breakage rate in a planetary ball mill. Adv Powder Technol. 1991;2:91–101.
   Google Scholar
• Staniforth JN, Harris H, Morton DAV, Bannister R, inventors; Vectura Limited, assignee. Pharmaceutical compositions for inhalation. US patent, US 8048451 B2,2011 Nov 1.
   Google Scholar
• Begat P, Price R, Harris H, et al. The influence of force control agents on the cohesive-adhesive balance in dry powder inhaler formulations. KONA Powder Part J. 2005;23:109–21.
   Google Scholar
• Begat P, Morton DAV, Shur J, et al. The role of force control agents in high-dose dry powder inhaler formulations. J Pharm Sci. 2009;98:2770–83.
   PubMed Web of Science ®Google Scholar
• Pfeffer R, Dave RN, Wei D, Ramlakhan M. Synthesis of engineered particulates with tailored properties using dry particle coating. Powder Technol. 2001;117:40–67.
   Web of Science ®Google Scholar
• Tao C, Miessen M, Pilgram P, Passerini S, Winter M, inventors; Evonik Litarion Gmbh, assignee. Electrode material having a high capacity. US Patent, US 20130337334 A1, 2013.
   Google Scholar
• Zhou QT, Qu L, Larson I, Stewart PJ, Morton DAV. Improving aerosolization of drug powders by reducing powder intrinsic cohesion via a mechanical dry coating approach. Int J Pharm. 2010;394:50–9.
   PubMed Web of Science ®Google Scholar
• Zhou QT, Armstrong B, Larson I, et al. Understanding the influence of powder flowability, fluidization and de-agglomeration characteristics on the aerosolization of pharmaceutical model powders. Eur J Pharm Sci. 2010;40:412–21.
   PubMed Web of Science ®Google Scholar
• Zhou QT, Qu L, Gengenbach T, et al. Effect of surface coating with magnesium stearate via mechanical dry powder coating approach on the aerosol performance of micronized drug powders from dry powder inhalers. AAPS PharmSciTech. 2013;14:38–44.
   PubMed Web of Science ®Google Scholar
• Zhou QT, Qu L, Gengenbach T, et al. Investigation of the extent of surface coating via mechanofusion with varying additive levels and the influences on bulk powder flow properties. Int J Pharm. 2011;413:36–43.
   PubMed Web of Science ®Google Scholar
• Kumon M, Suzuki M, Kusai A, et al. Novel approach to DPI carrier lactose with mechanofusion process with additives and evaluation by IGC. Chem Pharm Bull. 2006;54:1508–14.
   PubMed Web of Science ®Google Scholar
• Swaminathan V, Cobb J, Saracovan I. Measurement of the surface energy of lubricated pharmaceutical powders by inverse gas chromatography. Int J Pharm. 2006;312:158–65.
   PubMed Web of Science ®Google Scholar
• Telko MJ, Hickey AJ. Dry powder inhaler formulation. Respir Care. 2005;50:1209–27.
   PubMedGoogle Scholar
• Chen D. 2009. Hygroscopicity of pharmaceutical crystals: Retrieved from the University of Minnesota digital conservancy. Available from: http://conservancy.umn.edu/handle/11299/47878 [last accessed on 20/08/2016].
   Google Scholar
• Ward GH, Schultz RK. Process-induced crystallinity changes in albuterol sulphate and its effect on powder physical stability. Pharm Res. 1995;12:773–9.
   PubMed Web of Science ®Google Scholar
• Zografi G. States of water associated with solids. Drug Dev Ind Pharm. 1988;14:1905–26.
   Web of Science ®Google Scholar
• Hancock BC, Zografi G. The relationship between the glass transition temperature and the water content of amorphous pharmaceutical solids. Pharm Res. 1994;11:471–7.
   PubMed Web of Science ®Google Scholar
• Hickey AJ, Gonda I, Irwin WJ, Fildes FJ. Effect of hydrophobic coating on the behavior of a hydroscopic aerosol powder in an environment of controlled temperature and relative humidity. J Pharm Sci. 1990;79:1009–14.
   PubMed Web of Science ®Google Scholar
• Lucas P, Anderson K, Potter UJ, Stanifoth JN. Enhancement of small particle size dry powder aerosol formulations using an ultra low density additive. Pharm Res. 1999;16:1643–7.
   PubMed Web of Science ®Google Scholar
• Balani PN, Ng WK, Tan RBH, Chan SY. Influence of excipients in comilling on mitigating milling-induced amorphization or structural disorder of crystalline pharmaceutical actives. J Pharm Sci. 2010;99:2462–74.
   PubMed Web of Science ®Google Scholar
• Balani PN, Wong SY, Ng WK, Widjaja E, Tan RB, Chan SY. Influence of polymer content on stabilizing milled amorphous salbutamol sulphate. Int J Pharm 2010;391:125–36.
   PubMed Web of Science ®Google Scholar
• Curtin V, Amharar Y, Gallagher KH, et al. Reducing mechanical activation-induced amorphisation of salbutamol sulphate by co-processing with selected carboxylic acids. Int J Pharm. 2013;456:508–16.
   PubMed Web of Science ®Google Scholar